Page 36 - MBCA_FULL REPORT_FINAL_FOR_WEB
P. 36

Interviews with Key

                                      Opinion Leaders



                                      The qualitative part of our research landscape analysis included interviews with experts from
                                      various sectors relevant to MBC research, including advocacy and nonprofit organizations,
                                      academic and medical institutions, government agencies, pharmaceutical and biotechnology
                                      organizations, professional societies, and clinical trials cooperative groups (a complete list can
                                      be found in Appendix 2).

                                      All Alliance members were asked to suggest experts they believed we should interview,
                                      including members of their organization’s medical and scientific advisory boards or external
                                      scientists believed to be leaders in metastatic research. In addition, we identified experts to
                                      be interviewed from those listed as the principal investigator on multiple awards from the MBC
                                      Grants Dataset. The experts interviewed had expertise in basic laboratory research, clinical trial
                                      design and execution, health care and research policy, patient-reported outcomes, and quality
                                      of life research.

                                      Seven questions were asked of each KOL interviewed:

                                        1.   What exciting scientific opportunities do you see for advancing our understanding of
                                            metastasis?
                                        2.   What do you think is the most promising target for developing new therapeutics aimed
                                            at metastasis?
                                                 a.   Cancer stem cells in tumors
                                                 b.   Cell invasion from the breast
                                                 c.   Tumor dormancy
                                                 d.  Tumor cell avoidance of immune surveillance (“immune escape”)
                                                 e.   End-organ microenvironment
                                                 f.   Cell signaling and proliferation
                                                 g.  Other

                                        3.   What gaps or roadblocks exist that hinder advances in MBC research?

                                        4.  What role do you see for markers or circulating tumor cells, circulating tumor DNA,
                                            or other?

                                                 a.   Companion diagnostics (for new agents)

                                        5.   Can you describe MBC clinical trials you are involved with conducting?
                                                 a.   Challenges in designing and conducting trials for MBC

                                                 b.   Current pipeline of trials or products planned for MBC trials
                                        6.  Are there other aspects of MBC research we should discuss?

         36                             7.   Whom else should we interview?

                                      Each interview was conducted by 2 Alliance staff. Each interview was recorded and the
                                      interviewee was de-identified. All responses and interviewer notes were manually logged in
                                      a spreadsheet. The final spreadsheet was reviewed by 2 Alliance staff to identify and extract
                                      common topics: any topic noted by 3 or more respondents is included in the results section.
   31   32   33   34   35   36   37   38   39   40   41